Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D

Translational Psychiatry

Volumn 2, Issue , 2012, Pages

  Adkins, D E ^a   Clark, S L ^a   Aberg K ^a   Hettema, J M ^b   Bukszar J ^a   McClay, J L ^a   Souza, R P ^c   Van Den Oord, E J C G ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

citalopram; depression; genome wide association study; pharmacogenomics; side effects; STAR*D

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; FRAGILE HISTIDINE TRIAD PROTEIN;

ANORGASMIA; AOX2P GENE; ARTICLE; BLURRED VISION; BODY BURDEN; CHROMOSOME 13; CONSTIPATION; COORDINATION DISORDER; DEPRESSION; DIARRHEA; DIZZINESS; DRY SKIN; DYSURIA; EGFLAM GENE; EMID2 GENE; ERECTILE DYSFUNCTION; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEADACHE; HEART PALPITATION; HUMAN; HYPERHIDROSIS; HYPOACTIVE SEXUAL DESIRE DISORDER; LAMA1 GENE; MAJOR CLINICAL STUDY; MALE; MENSTRUAL IRREGULARITY; MENTAL PATIENT; NAUSEA AND VOMITING; PHARMACOGENOMICS; PRURITUS; RASH; RTP2 GENE; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP DISORDER; THORAX PAIN; TREMOR; URINARY FREQUENCY; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FACTOR ANALYSIS, STATISTICAL; FEMALE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84863732160     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2012.57     Document Type: Article

References (80)

1. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 617-627. (Pubitemid 40973437)
2. Mykletun A, Bjerkeset O, Dewey M, Prince M, Overland S, Stewart R. Anxiety, depression, and cause-specific mortality: The HUNT study. Psychosom Med 2007; 69: 323-331. (Pubitemid 46800292)
3. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006; 7: 137-151. (Pubitemid 43151600)
4. Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Progr Neuro-Psychopharmacol Biol Psychiatry 2003; 27: 85-102. (Pubitemid 36131110)
5. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28-40. (Pubitemid 43050100)
6. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008; 358: 252-260.
7. Bull SA, Hu XH, Hunkeler EM, Lee JY, Ming EE, Markson LE et al. Discontinuation of use and switching of antidepressants - influence of patient-physician communication. JAMA 2002; 288: 1403-1409. (Pubitemid 35025915)
8. Bull SA, Hunkeler EM, Lee JY, Rowland CR, Williamson TE, Schwab JR et al. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother 2002; 36: 578-584. (Pubitemid 34270268)
9. Mitchell AJ. High medication discontinuation rates in psychiatry - how often is it understandable? J Clin Psychopharmacol 2006; 26: 109-112. (Pubitemid 43740332)
10. Maddox JC, Levi M, Thompson C. The compliance with antidepressants in general practice. J Psychopharmacol 1994; 8: 48-53. (Pubitemid 24092317)
11. Franchini L, Serretti A, Gasperini M, Smeraldi E. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res 1998; 32: 255-259. (Pubitemid 28410114)
12. Malhotra AK, Murphy Jr GM, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004; 161: 780-796. (Pubitemid 38625331)
13. Oreilly RL, Bogue L, Singh SM. Pharmacogenetic response to antidepressants in a multicase family with affective disorder. Biol Psychiatry 1994; 36: 467-471. (Pubitemid 24308558)
14. Pare CMB, Mack JW. Differentiation of 2 genetically specific types of depression by response to antidepressant drugs. J Med Genet 1971; 8: 306-309.
15. Zobel A, Maier W. Pharmacogenetics of antidepressive treatment. Eur Arch Psychiatry Clin Neurosci 2010; 260: 407-417.
16. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010; 15: 473-500.
17. Porcelli S, Drago A, Fabbri C, Gibiino S, Calati R, Serretti A. Pharmacogenetics of antidepressant response. J Psychiatry Neurosci 2011; 36: 87-113.
18. Ayala ME. Brain serotonin, psychoactive drugs, and effects on reproduction. Cent Nerv Syst Agents Med Chem 2009; 9: 258-276.
19. Segraves RT. Effects of psychotropic drugs on human erection and ejaculation. Arch Gen Psychiatry 1989; 46: 275-284. (Pubitemid 19078265)
20. Pollack MH, Reiter S, Hammerness P. Genitourinary and sexual adverse effects of psychotropic medication. Int J Psychiatry Med 1992; 22: 305-327. (Pubitemid 23084018)
21. Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. Science 2008; 322: 881-888.
22. Aberg K, Adkins DE, Bukszar J, Webb BT, Caroff SN, Miller del D et al. Genomewide association study of movement-related adverse antipsychotic effects. Biol Psychiatry 2010; 67: 279-282.
23. Adkins DE, Aberg K, McClay JL, Bukszar J, Zhao Z, Jia P et al. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol Psychiatry 2011; 16: 321-332.
24. Adkins DE, Aberg K, McClay JL, Hettema JM, Kornstein SG, Bukszar J et al. A genomewide association study of citalopram response in major depressive disorder-a psychometric approach. Biol Psychiatry 2010; 68: e25-e27.
25. McClay JL, Adkins DE, Aberg K, Bukszar J, Khachane AN, Keefe RS et al. Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology 2011; 36: 616-626.
26. McClay JL, Adkins DE, Aberg K, Stroup S, Perkins DO, Vladimirov VI et al. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry 2011; 16: 76-85.
27. Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 2010; 67: 133-138.
28. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004; 25: 119-142. (Pubitemid 38230109)
29. Wisniewski SR, Rush AJ, Balasubramani GK, Trivedi MH, Nierenberg AA. Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract 2006; 12: 71-79. (Pubitemid 44284089)
30. Bollen KA. Structural Equations with Latent Variables. Wiley: New York, 1989.
31. Loehlin JC. Latent Variable Models: An Introduction to Factor, Path, and Structural Equation Analysis. Lawrence Erlbaum Associates: Mahwah, NJ, 2004.
32. van den Oord EJ, Adkins DE, McClay J, Lieberman J, Sullivan PF. A systematic method for estimating individual responses to treatment with antipsychotics in CATIE. Schizophr Res 2009; 107: 13-21.
33. Cohen J. The cost of dichotomization. Appl Psychol Meas 1983; 7: 249-253.
34. Muthén LK, Muthén BO. Mplus User's Guide, 6th edn. Muthén & Muthén: Los Angeles, CA, 1998-2010.
35. Nunnally JC, Bernstein IH. Psychometric Theory, 3rd edn. McGraw-Hill: New York, 1994, p xxiv, 752pp.
36. Demyttenaere K, Albert A, Mesters P, Dewe W, De Bruyckere K, Sangeleer M. What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors? J Clin Psychiatry 2005; 66: 859-863. (Pubitemid 41032827)
37. Barbee JG. Mixed symptoms and syndromes of anxiety and depression: diagnostic, prognostic, and etiologic issues. Ann Clin Psychiatry 1998; 10: 15-29. (Pubitemid 28258682)
38. Regier DA, Rae DS, Narrow WE, Kaelber CT, Schatzberg AF. Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders. Br J Psychiatry 1998; 173: 24-28. (Pubitemid 28312194)
39. Zimmerman M, Mattia JI. The reliability and validity of a screening questionnaire for 13 DSM-IV Axis I disorders (the psychiatric diagnostic screening questionnaire) in psychiatric outpatients. J Clin Psychiatry 1999; 60: 677-683. (Pubitemid 29503648)
40. Goldstein H. Multilevel Statistical Models. Arnold: London, 1995.
41. Searle SR, Casella G, McCuloch CE. Variance Components. Wiley: New York, 1992.
42. Pinheiro JC, Bates DM. Mixed-EffectsModels in S and S-plus. Springer: New York, NY, 2000.
43. Willett JB, Singer JD, Martin NC. The design and analysis of longitudinal studies of development and psychopathology in context: Statistical models and methodological recommendations. Dev Psychopathol 1998; 10: 395-426. (Pubitemid 128433129)
44. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38: 963-974.
45. Siddiqui O, Hung HMJ, O'Neill R. MMRM vs LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharmaceut Statist 2009; 19: 227-246.
46. Aberg K, Adkins DE, Liu Y, McClay JL, Bukszar J, Jia P et al. Genome-wide association study of antipsychotic-induced QTc interval prolongation. Pharmacogenom J 2012; 12: 165-172.
47. McClay JL, Adkins DE, Aberg K, Bukszar J, Khachane AN, Keefe RSE et al. Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology 2011; 36: 616-626.
48. Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet 2005; 76: 887-893. (Pubitemid 40563110)
49. Wittke-Thompson JK, Pluzhnikov A, Cox NJ. Rational inferences about departures from Hardy-Weinberg equilibrium. Am J Hum Genet 2005; 76: 967-986. (Pubitemid 40705433)
50. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575. (Pubitemid 47330214)
51. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-909. (Pubitemid 44141658)
52. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc Ser B 1995; 57: 289-300.
53. Brown BW, Russell K. Methods correcting for multiple testing: operating characteristics. Statist Med 1997; 16: 2511-2528. (Pubitemid 27490058)
54. Lei SF, Yang TL, Tan LJ, Chen XD, Guo Y, Guo YF et al. Genome-wide association scan for stature in Chinese: evidence for ethnic specific loci. Hum Genet 2009; 125: 1-9.
55. Liu YZ, Guo YF, Wang L, Tan LJ, Liu XG, Pei YF et al. Genome-wide association analyses identify SPOCK as a key novel gene underlying age at menarche. PLoS Genet 2009; 5: e1000420.
56. Beecham GW, Martin ER, Li YJ, Slifer MA, Gilbert JR, Haines JL et al. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet 2009; 84: 35-43.
57. Black MA. A note on the adaptive control of false discovery rates. J R Stat Soc Ser B 2004; 66: 297-304. (Pubitemid 38652721)
58. Storey J. The positive false discovery rate: a Bayesian interpretation and the q-value. Ann Stat 2003; 31: 2013-2035. (Pubitemid 38293903)
59. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003; 100: 9440-9445. (Pubitemid 37033947)
60. Leimeister C, Steidl C, Schumacher N, Erhard S, Gessler M. Developmental expression and biochemical characterization of Emu family members. Dev Biol 2002; 249: 204-218.
61. Rada JA, Cornuet PK, Hassell JR. Regulation of corneal collagen fibrillogenesis in vitro by corneal proteoglycan (Lumican and Decorin) core proteins. Exp Eye Res 1993; 56: 635-648. (Pubitemid 23183821)
62. Lim J, Hao T, Shaw C, Patel AJ, Szabo G, Rual JF et al. A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. Cell 2006; 125: 801-814. (Pubitemid 43732348)
63. Pasaje CF, Kim JH, Park BL, Cheong HS, Kim MK, Choi IS et al. A possible association of EMID2 polymorphisms with aspirin hypersensitivity in asthma. Immunogenetics 2011; 63: 13-21.
64. Yurchenco PD, Patton BL. Developmental and pathogenic mechanisms of basement membrane assembly. Curr Pharm Design 2009; 15: 1277-1294.
65. Haralson MA, Hassell JR. Extracellular Matrix: A Practical Approach. IRL Press/Oxford University Press: Ithaca, NY/Oxford, 1995.
66. Yoon KA, Park JH, Han J, Park S, Lee GK, Han JY et al. A genome-wide association study reveals susceptibility variants for non-small cell lung cancer in the Korean population. Hum Mol Genet 2010; 19: 4948-4954.
67. Gylfe AE, Sirkia J, Ahlsten M, Jarvinen H, Mecklin JP, Karhu A et al. Somatic mutations and germline sequence variants in patients with familial colorectal cancer. Int J Cancer 2010; 29: 29.
68. Akasaka H, Katsuya T, Saitoh S, Sugimoto K, Ohnishi H, Congrains A et al. A promoter polymorphism of lamin A/C gene is an independent genetic predisposition to arterial stiffness in a Japanese general population (the Tanno and Sobetsu study). J Atheroscler Thromb 2009; 16: 404-409.
69. Bailey SD, Xie C, Do R, Montpetit A, Diaz R, Mohan V et al. Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. Diabet Care 2010; 33: 2250-2253.
70. Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE et al. Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch Gen Psychiatry 2008; 65: 683-693. (Pubitemid 351787239)
71. Flachsbart F, Franke A, Kleindorp R, Caliebe A, Blanche H, Schreiber S et al. Investigation of genetic susceptibility factors for human longevity - a targeted nonsynonymous SNP study. Mutat Res 2010; 694: 13-19.
72. Kimura K, Wakamatsu A, Suzuki Y, Ota T, Nishikawa T, Yamashita R et al. Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes. Genome Res 2006; 16: 55-65. (Pubitemid 43048934)
73. Long MY, Langley CH. Natural-selection and the origin of jingwei, a chimeric processed functional gene in Drosophila. Science 1993; 260: 91-95. (Pubitemid 23122751)
74. Hirotsune S, Yoshida N, Chen A, Garrett L, Sugiyama F, Takahashi S et al. An expressed pseudogene regulates the messenger-RNA stability of its homologous coding gene. Nature 2003; 423: 91-96. (Pubitemid 36569588)
75. Tam OH, Aravin AA, Stein P, Girard A, Murchison EP, Cheloufi S et al. Pseudogene-derived small interfering RNAs regulate gene expression in mouse oocytes. Nature 2008; 453: U534-U538.
76. Geisert EE, Lu L, Freeman-Anderson NE, Templeton JP, Nassr M, Wang X et al. Gene expression in the mouse eye: an online resource for genetics using 103 strains of mice. Mol Vis 2009; 15: 1730-1763.
77. Sato S, Omori Y, Katoh K, Kondo M, Kanagawa M, Miyata K et al. Pikachurin, a dystroglycan ligand, is essential for photoreceptor ribbon synapse formation. Nat Neurosci 2008; 11: 923-931.
78. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007; 316: 1336-1341. (Pubitemid 46871654)
79. Harismendy O, Notani D, Song XY, Rahim NG, Tanasa B, Heintzman N et al. 9p21 DNA variants associated with coronary artery disease impair interferon-gamma signalling response. Nature 2011; 470: 264-268.
80. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 2010; 26: 2336-2337.